RYTM

Rhythm Pharmaceuticals Stock Analysis

AI Rating

Neutral
  • Quality1/10
  • Growth↑ 6/10
  • Momentum↑ 6/10
Rhythm Pharmaceuticals sales and earnings growth
RYTM Growth
Good
  • Revenue Y/Y↑ 54.92%
  • EPS Y/Y↑ 28.41%
  • FCF Y/Y↑ 12.29%
Rhythm Pharmaceuticals gross and profit margin trends
RYTM Profitability
Neutral
  • Gross margin ↑ 89.40%
  • EPS margin↓ -113.40%
  • ROIC↓ -84.70%
Rhythm Pharmaceuticals net debt vs free cash flow
RYTM Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -8.0

Rhythm Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗